Fresenius Group Overview

The Health Care Group
Stories
Archive „Stories“
Investors
Contact

Fresenius SE & Co. KGaA

Investor Relations

+49 (0) 6172 608-2485
ir-fre@fresenius.com
Media
- News
- Social Media
- Calendar
- Contacts
- Media Center
Contact

Matthias Link

Senior Vice President Corporate Communications

T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Careers
Menu
Filter results
- Chapter
- Format
  - Website (0)
  - PDF (0)
Share
- Facebook
- Twitter
- LinkedIn
- Xing
- Google+
- E-Mail
Services
- Deutsch
- Print
- Contact
- RSS

From a local pharmacy to a global corporation

As a leading global health care group we are dedicated to medicine and human health - values we have upheld since our founding as a pharmacy lab in 1912.
Read the story
Health Prevention

The Helios Prevention Centers offers programs for individual prevention and company health management.
Learn more
A polyclinic in Ghana

Fresenius Vamed plans and builds health care facilities around the world – even in undeveloped regions of Africa.

Read the story
17,962 miles halfway around the world

A dialysis machine's journey from Fresenius Medical Care's plant in Schweinfurt, Germany, to its destination in the Australian Outback.

Read the story

News

Brief News
Fresenius Helios develops system to measure patient safety

Fresenius Helios has developed a new system for measuring patient safety, and is introducing it in all 86 Helios hospitals across Germany. The new system will complement the company’s existing quality management system and combine internationally established patient safety indicators with various indicators that Helios has developed through clinical practice. These include measurements on such indicators as false diagnoses, medication errors and patient falls. When Helios begins reporting the results next year, it will be the first German hospital operator to provide patient safety data that can be compared internationally.

September 18, 2019Fresenius Helios

Brief News
Fresenius Kabi opens research and development center for biosimilars in Switzerland

Fresenius Kabi has opened a new research and development center for biosimilars in Eysins, in the Swiss canton of Vaud. The facility, in which the company invested about €15 million, will strengthen Fresenius Kabi’s capability to develop new biosimilars, particularly in the areas of autoimmune diseases and oncology. A biosimilar is a drug that is “similar” to another, already approved biologic drug. More than 100 employees representing over 20 nationalities work at the Eysins site, and the company plans to expand the workforce in the near future.

September 18, 2019Fresenius Kabi
Brief News
Fresenius SE & Co. KGaA included in Dow Jones Sustainability Index

Fresenius will be included in the Dow Jones Sustainability Index Europe (DJSI Europe) for the first time as from 23 September 2019. The selected companies must demonstrate continuous improvement with regard to sustainability and are assessed by analysts from asset manager RobecoSAM.

September 17, 2019Fresenius

Brief News
2020 DRG inflator for German hospitals set at 3.66%

The price increase for hospital services in Germany has been set at 3.66% for 2020. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.

September 16, 2019Fresenius Helios
Brief News
Fresenius Helios launches digital portal for patients

Fresenius Helios patients in Germany can soon start accessing letters from their doctors, test results and other medical documents over an online platform – the Helios Patients Portal. This new portal can also be used to make appointments. The confidentiality of patient data is assured through the use of two-factor authentification. All 86 of the company’s hospitals, 126 medical care centers and eight prevention centers throughout Germany are being gradually linked to the Helios Patients Portal. The company is also developing a portal for doctors.

September 11, 2019Fresenius Helios

Fresenius Medical Care’s publishes annual medical report

September 09, 2019Fresenius Medical Care
Brief News
Fresenius Medical Care builds new laboratory in Mississippi

Spectra Laboratories, a wholly-owned subsidiary of Fresenius Medical Care North America, broke ground on a 200,000-square-foot (approx. 18,500 square meters) laboratory in Southaven, Mississippi yesterday. The project is expected to create more than 300 jobs over the next three years. Spectra Laboratories offers renal-specific laboratory services, using state-of-the-art equipment, automated specimen processing, and reporting applications. At Spectra’s new build-to-suit facility, employees will conduct comprehensive testing, analysis, and reporting to ensure the best possible outcomes for patients.

September 06, 2019Fresenius Medical Care

Fresenius Medical Care invests EUR 60 million in Unicyte

September 05, 2019Fresenius Medical Care
Fresenius Helios acquires two hospitals in Colombia

September 02, 2019Fresenius Helios

Fresenius Medical Care appoints Helen Giza as Chief Financial Officer

August 27, 2019Fresenius Medical Care
Brief News
Fresenius Vamed completes main university hospital building in Kiel

After four years of construction Fresenius Vamed has completed the new main building at University Hospital Schleswig-Holstein (UKSH) in Kiel. The completion marks the first milestone in the modernization of Germany’s second-largest university hospital, with the main building of the Lübeck location scheduled to open in November. The project includes new construction and the comprehensive renovation of the two university hospital locations, some 80 kilometers (50 miles) apart in Schleswig-Holstein state, and their technical management through 2044. With a total volume of €1.7 billion, the UKSH’s modernization is currently the biggest public-private partnership project in Europe’s healthcare sector.

August 20, 2019Fresenius Vamed

Brief News
Fresenius Helios expands preventive medicine offering

Fresenius Helios has opened a new Helios Prevention Center in Berlin, as the company continues the expansion of its occupational medicine activities into a standalone business area. The modern, 440-square-meter (4,700-square-foot) center in the heart of Germany’s capital offers comprehensive check-ups from a single source. HCP patients are accompanied throughout the check-up by their own personal physician, and do not have to search for the right department for their next test, deal with different contact persons, or face long waiting times. And if a test turns up something requiring medical treatment, the patient has direct access to the Helios healthcare network and an exclusive hotline for making appointments with specialists.

August 05, 2019Fresenius Helios
Fresenius raises Group sales growth guidance after good second quarter

July 30, 2019Fresenius

Fresenius Medical Care on track to achieve full-year targets after solid second quarter

July 30, 2019Fresenius Medical Care
Fresenius Medical Care celebrates 40th anniversary of Schweinfurt plant, company’s largest for dialysis machines

July 19, 2019Fresenius Medical Care

Fresenius Medical Care sees U.S. plans for changes to kidney disease care as positive reinforcement of company’s strategy

July 10, 2019Fresenius Medical Care
Brief News
Fresenius Medical Care North America invests in innovative medical wearable venture

Fresenius Medical Care North America (FMCNA) has announced an investment in BioIntelliSense, a Denver-based company that is developing a medical grade data services platform for continuous remote health monitoring, predictive analytics and algorithmic clinical insights. FMCNA is committed to bringing its expertise in advanced analytics and artificial intelligence to the development and deployment of this system in cooperation with BioIntelliSense. The aim is to jointly create clinical pathways that can alert clinicians to the need for early intervention, potentially preventing patients from complications and, thus, reducing unnecessary as well as costly hospitalizations. The investment, therefore, supports Fresenius Medical Care’s strategic goal to improve monitoring, interventions and outcomes for patients living with kidney disease and other chronic illnesses in order to increase their quality of life.

July 09, 2019Fresenius Medical Care

Fresenius Medical Care expands clinical research activities

July 03, 2019Fresenius Medical Care
Fresenius Medical Care successfully places USD bonds

June 14, 2019Fresenius Medical Care

Fresenius Medical Care organizes Organ Donation Day

June 06, 2019Fresenius Medical Care
Brief News
S&P upgrades Fresenius to BBB with stable outlook

Standard & Poor’s has revised Fresenius’ corporate credit rating to BBB with a stable outlook from BBB- with a positive outlook. Fresenius is rated investment grade by the three leading rating agencies Standard & Poor’s (BBB/stable), Moody's (Baa3/stable) and Fitch (BBB-/stable).

May 23, 2019Fresenius

S&P upgrades Fresenius Medical Care to BBB with stable outlook

Standard & Poor’s has upgraded Fresenius Medical Care’s corporate credit rating to BBB with a stable outlook from BBB- with a positive outlook.
May 23, 2019Fresenius Medical Care
Annual General Meeting: Fresenius on course for continued growth, 26th straight increase in dividend approved

May 17, 2019Fresenius

Fresenius Medical Care stays on course for growth – Annual General Meeting approves 22nd straight dividend increase

May 16, 2019Fresenius Medical Care
Brief News
Fresenius Kabi launches biosimilar adalimumab IDACIO® in Germany

Fresenius Kabi is launching its first biosimilar in Germany following the European Commission (EC) granting marketing authorization for IDACIO® for all indications of the reference medicine in the areas of rheumatology, gastroenterology and dermatology.

May 03, 2019Fresenius Kabi

Fresenius makes solid start to 2019 and confirms Group guidance

May 02, 2019Fresenius
Fresenius Medical Care with a good start into 2019

May 02, 2019Fresenius Medical Care

Brief News
Fresenius Kabi receives European Commission approval for adalimumab biosimilar IDACIO®

The European Commission (EC) granted Fresenius Kabi the marketing authorization for IDACIO®, an adalimumab biosimilar, for all indications of the reference medicine. With this EC approval, IDACIO® is the first approved molecule of the Fresenius Kabi biosimilars portfolio.

April 03, 2019Fresenius Kabi
Fresenius Medical Care resolves FCPA investigation

March 29, 2019Fresenius Medical Care

Fresenius Medical Care appoints Dr. Frank Maddux as Global Chief Medical Officer

March 20, 2019Fresenius Medical Care

Disclaimer All news

October 29, 2019 | Bad Homburg, Germany

Conference Call Q3 2019, Fresenius

Import (ICS)

Library

All Downloads

Follow us

The Health Care Group

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com

Contact

Visit us